A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Anti-tumor Activity of SYHA1801 Capsules in Patients With Advanced Solid Tumors.
Latest Information Update: 05 Jul 2023
At a glance
- Drugs SYHA 1801 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors CSPC ZhongQi Pharmaceutical Technology
Most Recent Events
- 06 May 2020 Status changed from not yet recruiting to recruiting.
- 20 Mar 2020 New trial record